Bolt Biotherapeutics, Inc. (BOLT): Price and Financial Metrics

Bolt Biotherapeutics, Inc. (BOLT): $1.15

0.02 (+1.77%)

POWR Rating

Component Grades








Add BOLT to Watchlist
Sign Up

Industry: Biotech




#68 of 363

in industry

BOLT Price/Volume Stats

Current price $1.15 52-week high $2.03
Prev. close $1.13 52-week low $0.84
Day low $1.08 Volume 101,698
Day high $1.15 Avg. volume 123,240
50-day MA $1.20 Dividend yield N/A
200-day MA $1.13 Market Cap 43.85M

BOLT Stock Price Chart Interactive Chart >

Bolt Biotherapeutics, Inc. (BOLT) Company Bio

Bolt Biotherapeutics, Inc. operates as a biotechnology company. The Company develops immune-stimulating antibody conjugates, a new class of cancer therapeutics, which systemically-administered and uncover the immune system to induce anti-tumor immunity. Bolt Biotherapeutics serves healthcare industry in the United States.

BOLT Latest News Stream

Event/Time News Detail
Loading, please wait...

BOLT Latest Social Stream

Loading social stream, please wait...

View Full BOLT Social Stream

Latest BOLT News From Around the Web

Below are the latest news stories about BOLT BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BOLT as an investment opportunity.

Pacira Appoints Frank D. Lee as Chief Executive Officer

-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (th

Yahoo | December 21, 2023

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial design and rationale to be presented at the 2023 San Antonio Breast Cancer Symposium on Wednesday, December 6 REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of

Yahoo | December 5, 2023

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | November 20, 2023

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing improved clinical efficacy and longer durability; FDA Orphan Drug Designation granted for the BDC-1001 in gastric cancersFirst patient administered BDC-3042 in a Phase 1/2 dose-escalation and expansion clinical studyCash balance of $141.4 million as of September 30, 2023 anticipated to fund key miles

Yahoo | November 9, 2023

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, Nov. 14, 2023, at 8:35 a.m. EDT (5:35 a.m. PDT) in New York, New York. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at

Yahoo | November 7, 2023

Read More 'BOLT' Stories Here

BOLT Price Returns

1-mo 3.60%
3-mo 3.14%
6-mo 13.86%
1-year -24.34%
3-year -94.86%
5-year N/A
YTD 2.68%
2023 -13.85%
2022 -73.47%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!